[go: up one dir, main page]

CL2012000102A1 - Compuestos derivados de (fenil/piridin)-etinil-imidazol, antagonistas del los receptores metabotropicos de glutamato (mglur5); procedimiento de preparacion; y su uso para el tratamiento y prevencion del alzheimer, demencia senil, parkinson, entre otras. - Google Patents

Compuestos derivados de (fenil/piridin)-etinil-imidazol, antagonistas del los receptores metabotropicos de glutamato (mglur5); procedimiento de preparacion; y su uso para el tratamiento y prevencion del alzheimer, demencia senil, parkinson, entre otras.

Info

Publication number
CL2012000102A1
CL2012000102A1 CL2012000102A CL2012000102A CL2012000102A1 CL 2012000102 A1 CL2012000102 A1 CL 2012000102A1 CL 2012000102 A CL2012000102 A CL 2012000102A CL 2012000102 A CL2012000102 A CL 2012000102A CL 2012000102 A1 CL2012000102 A1 CL 2012000102A1
Authority
CL
Chile
Prior art keywords
etinyl
parkinson
alzheimer
antagonists
imidazole
Prior art date
Application number
CL2012000102A
Other languages
English (en)
Inventor
Eric Vieira
Georg Jaeschke
Lothar Lindemann
Jue Rgen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42358156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000102(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2012000102A1 publication Critical patent/CL2012000102A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de (fenil/piridin)-etinil-imidazol, antagonistas del los receptores metabotrópicos de glutamato; procedimiento de preparación; composición farmacéutica; y su uso para el tratamiento y prevención de enfermedad de Alzheimer, demencia senil, enfermedad de Parkinson, entre otras.
CL2012000102A 2009-07-17 2012-01-13 Compuestos derivados de (fenil/piridin)-etinil-imidazol, antagonistas del los receptores metabotropicos de glutamato (mglur5); procedimiento de preparacion; y su uso para el tratamiento y prevencion del alzheimer, demencia senil, parkinson, entre otras. CL2012000102A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09165780 2009-07-17

Publications (1)

Publication Number Publication Date
CL2012000102A1 true CL2012000102A1 (es) 2012-09-07

Family

ID=42358156

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000102A CL2012000102A1 (es) 2009-07-17 2012-01-13 Compuestos derivados de (fenil/piridin)-etinil-imidazol, antagonistas del los receptores metabotropicos de glutamato (mglur5); procedimiento de preparacion; y su uso para el tratamiento y prevencion del alzheimer, demencia senil, parkinson, entre otras.

Country Status (33)

Country Link
US (1) US8334287B2 (es)
EP (1) EP2456765B1 (es)
JP (1) JP5667182B2 (es)
KR (1) KR101431347B1 (es)
CN (1) CN102471309B (es)
AR (1) AR077481A1 (es)
AU (1) AU2010272585B2 (es)
BR (1) BR112012001092A2 (es)
CA (1) CA2765921C (es)
CL (1) CL2012000102A1 (es)
CO (1) CO6400142A2 (es)
CR (1) CR20110659A (es)
CY (1) CY1114186T1 (es)
DK (1) DK2456765T3 (es)
EC (1) ECSP12011611A (es)
ES (1) ES2411467T3 (es)
HR (1) HRP20130657T1 (es)
IL (1) IL216746A (es)
MA (1) MA33386B1 (es)
MX (1) MX2012000814A (es)
MY (1) MY156878A (es)
NZ (1) NZ596810A (es)
PE (1) PE20120397A1 (es)
PL (1) PL2456765T3 (es)
PT (1) PT2456765E (es)
RS (1) RS52901B (es)
RU (1) RU2527106C2 (es)
SG (1) SG178052A1 (es)
SI (1) SI2456765T1 (es)
TW (1) TWI423964B (es)
UA (1) UA107086C2 (es)
WO (1) WO2011006910A1 (es)
ZA (1) ZA201109451B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113223C2 (xx) * 2012-08-13 2016-12-26 Арилетинілпіримідини
US20170173008A1 (en) * 2014-03-19 2017-06-22 President And Fellows Of Harvard College Antimicrobial agents and screening methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL132318A0 (en) * 1997-04-24 2001-03-19 Ortho Mcneil Pharm Inc Substituted imidazoles useful in the treatment of inflammatory diseases
HUP0400570A3 (en) 2000-12-04 2004-09-28 Hoffmann La Roche Phenylethenyl or phenylethinyl heteroaril derivatives as glutamate receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
NZ543638A (en) * 2003-06-12 2008-05-30 Hoffmann La Roche Heteroaryl-substituted imidazole derivatives as glutamate receptor antagonists
US7452909B2 (en) * 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
HRP20080363T3 (hr) * 2004-06-01 2008-09-30 F. Hoffmann - La Roche Ag Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
DE602005007350D1 (de) 2004-06-01 2008-07-17 Hoffmann La Roche Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors
RS55585B1 (sr) 2006-11-22 2017-06-30 Clinical Research Associates LLC Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma

Also Published As

Publication number Publication date
CY1114186T1 (el) 2016-08-31
RS52901B (sr) 2014-02-28
ECSP12011611A (es) 2012-02-29
WO2011006910A1 (en) 2011-01-20
CN102471309B (zh) 2014-09-03
CA2765921A1 (en) 2011-01-20
CN102471309A (zh) 2012-05-23
CO6400142A2 (es) 2012-03-15
US8334287B2 (en) 2012-12-18
AR077481A1 (es) 2011-08-31
MA33386B1 (fr) 2012-06-01
TWI423964B (zh) 2014-01-21
MX2012000814A (es) 2012-03-14
RU2012104399A (ru) 2013-08-27
KR20120032033A (ko) 2012-04-04
NZ596810A (en) 2014-01-31
DK2456765T3 (da) 2013-05-27
SI2456765T1 (sl) 2013-06-28
KR101431347B1 (ko) 2014-08-19
UA107086C2 (ru) 2014-11-25
RU2527106C2 (ru) 2014-08-27
SG178052A1 (en) 2012-03-29
PT2456765E (pt) 2013-06-20
HK1169397A1 (en) 2013-01-25
PE20120397A1 (es) 2012-04-24
TW201116523A (en) 2011-05-16
AU2010272585B2 (en) 2013-11-07
IL216746A (en) 2015-03-31
US20110015202A1 (en) 2011-01-20
EP2456765A1 (en) 2012-05-30
PL2456765T3 (pl) 2013-09-30
JP5667182B2 (ja) 2015-02-12
AU2010272585A1 (en) 2012-01-19
MY156878A (en) 2016-04-15
IL216746A0 (en) 2012-03-01
CR20110659A (es) 2012-03-02
JP2012532913A (ja) 2012-12-20
BR112012001092A2 (pt) 2020-08-25
ZA201109451B (en) 2012-08-29
HRP20130657T1 (en) 2013-08-31
EP2456765B1 (en) 2013-05-01
ES2411467T3 (es) 2013-07-05
CA2765921C (en) 2017-04-18

Similar Documents

Publication Publication Date Title
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
JO3408B1 (ar) مركبات بترين سلفون اميد ثيازول و أوكسازول
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
CL2015000942A1 (es) Compuestos de benceno sustituido.
MX390264B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
MX388468B (es) Compuestos multicíclicos y métodos de uso de los mismos.
EA201071291A3 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
IL204437A (en) History of aryl cyclic profile and their use
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
CL2008001321A1 (es) Compuestos derivados de (cromanil o tiocromanil o naftalenil)-1,3-dihidroimidazol-2-tiona, inhibodores de dopamina betahidroxilasa; procedimiento de preparacion de enantiomeros (r) y (s) separados o en mezcla; composicion farmaceutica; y su uso en el tratamiento de ansiedad, jaqueca, trastornos cardiovasculares, entre otros.
MX2009004662A (es) Compuestos de pirazolina como antagonistas receptores de mineralocorticoides.
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CY1113820T1 (el) Παραγωγα 4-αλκοξυπυριδαζινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CL2010000804A1 (es) Compuestos derivados de 3-(1 h-pirrol-2-il-metil)-1 ,3-dihidro-2h-indol-2-ona; procedimientos de preparación de dichos compuestos; composición farmacéutica y combinación farmacéutica que los comprende; y su uso para el tratamiento de cáncer.
CL2011002965A1 (es) Compuestos derivados de piperidinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso de dichos compuestos para el tratamiento y/o profilaxis de trastornos cardiovasculares, tromboembolicos y/o tumores.
AR080172A1 (es) (r) -4- ((4-((4-(tetrahidrofuran-3-iloxi) benzo (d) isoxazol-3-iloxi)metil)piperidin-1-il)metil) tetrahidro-2h-piran-4-ol, un agonista parcial de receptores 5-ht4 y composiciones farmaceuticas que los comprenden
GT200600081A (es) Derivados de acetilenno